Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 5, 1996, Pages 451-461

  Harvie, Pierrot ^b   Omar, Rabeea F ^b   Dusserre, Nathalie ^b   Désormeaux, André ^b   Gourde, Pierrette ^b   Tremblay, Michel ^b   Beauchamp, Denis ^b   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

Antiviral evaluation; Hematotoxicity; Murine acquired immunodeficiency syndrome; Ribavirin

Indexed keywords

CD8 ANTIGEN; CONCANAVALIN A; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; HYPERGAMMAGLOBULINEMIA; LYMPHADENOPATHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT DISEASE; SPLENOMEGALY; SUPPRESSOR CELL; VIRUS INFECTION;

ANIMALIA; MURINAE; RODENTIA; UNIDENTIFIED RETROVIRUS;

EID: 0029831964     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608150-00003     Document Type: Article

References (58)

1. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986;30:201-5.
2. Smith RA, Wade M. Ribavirin: a broad spectrum antiviral agent. In: Stapleton T, ed. Studies with a broad spectrum antiviral agent. London: Royal Society of Medicine Services, 1986:99-118.
3. Knight V, McClung HW, Wilson SZ, et al. Ribavirin small-particle aerosol treatment of influenza. Lancet 1981;ii:945-9.
4. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
5. McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet 1984;i:1367-9.
6. Fernandez-Larsson R, Patterson JL. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol Pharmacol 1990;38:766-70.
7. Anonymous. Ribavirin for HIV-continuing smoke, not much fire [Editorial]. Lancet 1991;338:22-3.
8. Roberts RB, Laskin OL, Laurence J, et al. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987;42:365-73.
9. Roberts RB, Dickinson GM, Heseltine PNR, et al. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. J Acquir Immune Defic Syndr 1990; 3:884-92.
10. Roberts RB, Hollinger FB, Parks WP, et al. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. AIDS 1990;4:67-72.
11. Spanish Ribavirin Trial Group. Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Lancet 1991;338:6-9.
12. Gilson RJC, Semple M, Gill SK, Loveday C, Tedder RS, Weller IVD. Lack of suppression by ribavirin of HIV viraemia. Lancet 1992;339:1605-6.
13. The Ribavirin ARC Study Group. Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. J Acquir Immune Defic Syndr 1993;6:32-41.
14. Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987;41:546-55.
15. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
16. Baba M, Pauwels R, Balzarini J, Herdewijn P, deClercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987;31:1613-7.
17. Wray SK, Gilbert BE, Noall MW, Knight V. Mode of action of ribavirin: effect of nucleoside pool alterations on influenza virus transcription in vitro. Antiviral Res 1985;5:29-37.
18. Smith RA. Background and mechanism of action of ribavirin. In: Smith RA, Knight V, Smith JAD, eds. Clinical applications of ribavirin. New York: Academic Press, 1984:1-18.
19. Eriksson B, Helgstrand E, Johnsson NG, et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977;11:946-51.
20. Toltzis P, O'Connell K, Patterson JL. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob Agents Chemother 1988;32:492-7.
21. Morse III HC, Chattopadhyay SK, Makino M, Fredrickson TN, Hügin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 1992;6:607-21.
22. Chattopadhyay SK, Morse III HC, Makino M, Ruscetti SK, Hartley JW. Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci USA 1989;86:3862-6.
23. Hartley JW, Frederickson TN, Yetter RA, Makino M, Morse III HC. Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J Virol 1989; 63:1223-31.
24. Aziz DC, Hanna Z, Jolicoeur P. Severe immunodeficiency disease induced by defective murine leukaemia virus. Nature 1989;338:505-8.
25. Masuda A, Burton GF, Fuchs BA, et al. Follicular dendritic cell function and murine AIDS. Immunology 1994;81:41-6.
26. Masuda A, Burton GF, Szakal AK, Tew JG. Loss of follicular dendritic cells in murine-acquired immunodeficiency syndrome. Lab Invest 1995;73:511-20.
27. Hugin AW, Vacchio MS, Morse III HC. A virus-encoded "superantigen" in a retrovirus-induced immunodeficiency syndrome of mice. Science 1991;252:424-7.
28. Ohnota H, Okada Y, Ushijima H, Kitamura T, Komuro K, Mizuochi T. 3′-Azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/ 10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicrob Agents Chemother 1990;34:605-9.
29. Portnoi D, Stall AM, Schwartz D, Merigan TC, Herzenberg L, Basham T. Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. J Immunol 1990;144: 1705-10.
30. Basham T, Rios DC, Holdener T, Merigan TC. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis 1990;161:1006-9.
31. Basham T, Holdener T, Merigan T. Intermittent, alternating, and concurrent regimens of zidovudine and 2′-3′ dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. J Infect Dis 1991;163:869-72.
32. Phillips NC, Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992;79:1137-43.
33. Brandi G, Casabianca A, Schiavano GF, et al. Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model. Antivir Chem Chemother 1995;6:153-61.
34. Gazzinelli RT, Giese NA, Morse III HC. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994;180:2199-208.
35. Kort JJ, Eiseman JL. Interferon-gamma: a potent antiviral agent targeting macrophages infected with LP-BM5 murine leukemia virus, the causative agent of "AIDS" in mice. Can J Infect Dis 1992;3:115B-22B.
36. Nuovo GJ, Becker J, Burk MW, Margiotta M, Fuhrer J, Steigbigel RT. In situ detection of PCR-amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and advanced-state AIDS. J Acquir Immune Defic Syndr 1994;7:916-23.
37. Sei S, Kleiner DE, Kopp JB, et al. Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. J Infect Dis 1994;170: 325-33.
38. Rowe WP, Pugh WE, Hartley JW. Plaque assay techniques for murine leukemia viruses. Virology 1970;42:1136-9.
39. Klinman DM, Morse III HC. Characteristics of B cell proliferation and activation in murine AIDS. J Immunol 1989; 142:1144-9.
40. Mosier DE, Yetter RA, Morse III HC. Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J Exp Med 1985;161: 766-84.
41. + subset regulation in viral infection: preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol 1992;148:182-8.
42. Kim WK, Tang Y, Kenny JJ, Longo DL, Morse III HC. In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. J Virol 1994;68: 6767-9.
43. Powers CN, Peavy DL, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother 1982;22:108-14.
44. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379-83.
45. Schulman NR. Assessment of hematologic effect of ribavirin in humans. In: Smith RA, Knight V, Smith JAD, eds. Clinical applications of ribavirin. New York: Academic Press, 1984:79-92.
46. Canonico PG, Kastello MD, Spears CT, Brown JR, Jackson EA, Jenkins E. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984;74:155-62.
47. Weiss RC, Cox NR, Bourdreaux MK. Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 1993;16:301-16.
48. Harvie P, Désormeaux A, Gagné N, et al. Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 1995;9:701-7.
49. Kende M, Alving CR, Rill WL, Swartz GM, Canonico PG. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus in mice. Antimicrob Agents Chemother 1985;27:903-7.
50. Gangemi DJ, Nachtigal M, Barnhart D, Krech L, Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis 1987;155:510-7.
51. Désormeaux A, Harvie P, Perron S, et al. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 1994;8: 1545-53.
52. Désormeaux A, Bergeron MG. Targeting HIV with liposome-encapsulated antivirals. Zbl Bakt-Int J Med Microbiol 1995;282:225-31.
53. Dusserre N, Lessard C, Paquette N, et al. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, and pharmacokinetics. AIDS 1995;9:833-41.
54. Harvie P, Désormeaux A, Bergeron M-C, et al. Comparative pharmacokinetics, distribution in tissues and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′-3′ dideoxyinosine. Antimicrob Agent Chemother 1996;40:225-9.
55. Makabi-Panzu B, Lessard C, Perron S, et al. Comparison of cellular accumulation, tissue distribution, and anti-HIV activity of free and liposomal 2′,3′-dideoxycytidine. AIDS Res Hum Retrovir 1994;10:1463-70.
56. Makabi-Panzu B, Lessard C, Beauchamp D, et al. Uptake and binding of liposomal 2′,3′-dideoxycytidine by RAW 264.7 cells: a three-step process. J Acquir Immune Defic Syndr Hum Retrovir 1995;8:227-35.
57. Omar RF, Dusserre N, Désormeaux A, et al. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995;39:1973-8.
58. Balzarini J, Naesens L, Robins MJ, De Clercq E. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J Acquir Immune Defic Syndr 1990; 3:1140-7.